Abstract
(±)-(E)-4-Ethyl-2-[(E)-hydroxyimino] - 5 - nitro-3-hexenamide (FK409) shows both potent in vitro vasorelaxant and antiplatelet activities via nitric oxide (NO) generated spontaneously from the compound. In this study, we measured spontaneous NO-releasing rates of a series of FK409 derivatives, of which chain lengths or substituents were systematically modified, in sodium-phosphate buffer solution at pH 7.4. Furthermore, we studied their in vitro antiplatelet and vasorelaxant effects to evaluate relationships between spontaneous NO-releasing activities of FK409 analogs and their biological activities. FK409 derivatives were found to possess different spontaneous NO-releasing rates and biological activities according to their structural modification. In addition, these studies revealed a close correlation between NO-releasing rates of FK409 derivatives and their in vitro antiplatelet activities in human platelet-rich plasma, whereas the in vitro vasorelaxant activities of these compounds in isolated rat aorta did not correlate with the rates of NO liberation. The vasorelaxant effects were supposed to be affected by the structural properties of FK409 derivatives as well as their NO-releasing abilities.
Footnotes
-
Send reprint requests to: Dr. Yasuhiro Kita, Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 5-2-3, Tokodai, Tsukuba, Ibaraki 300-26, Japan.
- Abbreviations:
- FK409
- (±)-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide
- NO
- nitric oxide
- PB
- sodium-phosphate buffer
- ADP
- adenosine-5′-diphosphate
- cGMP
- guanosine 3′:5′-cyclic monophosphate
- NMR
- nuclear magnetic resonance
- ESR
- electron spin resonance
- SNP
- sodium nitroprusside
- ISDN
- isosorbide dinitrate
- DMSO
- dimethylsulfoxide
- carboxy-PTIO
- 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide
- Received August 26, 1996.
- Accepted March 12, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
